Abstract

The paper discusses the system of managing risks arising during preclinical studies (risks for the health of personnel and laboratory animals, as well as risks associated with sanitation of premises) as a way to improve and control the efficiency of processes and the safety of facilities involved in preclinical studies.The aim of the studywas to analyse the risk assessment system’s efficiency for improvement of drug safety assessment during preclinical studies in the context of animal care and use programmes.Materials and methods: the Failure Mode Effect Analysis (FMEA) method was used to assess the sanitary and hygienic conditions in laboratory animal facilities, as well as health status and welfare of laboratory animals and the attending personnel. The study checked the presence of pathogenic and opportunistic microflora as the main potential inconsistencies.Results: the risk assessment performed during monitoring of laboratory animal health, monitoring of surface cleanliness, and assessment of personnel health, helped to establish a list of the most dangerous pathogens that require stricter control. In order to reduce risks arising during preclinical studies, the following set of measures was proposed: monitoring of the living environment and health of laboratory animals, revision of therapeutic and preventive measures for laboratory animals (including adjustment of antibiotic treatment depending on antimicrobial resistance of microorganisms), monitoring of the personnel health status, taking measures to enhance the personnel vigilance with respect to their own health, prohibition to work at the premises for employees showing symptoms, control of how the employees showing symptoms observe the prohibition to work at the premises, organisation of periodic medical examinations for personnel having contact with laboratory animals.Conclusions: the risk-based assessment helped to identify the most dangerous potential inconsistencies (pathogenic and opportunistic microflora) and the necessary preventive measures to control and manage potential risk consequences.

Highlights

  • The paper discusses the system of managing risks arising during preclinical studies as a way to improve and control the efficiency of processes and the safety of facilities involved in preclinical studies

  • Analysis of health risks for personnel working with laboratory animals

  • Подписку на журнал можно оформитьВ каталоге агентства «Роспечать» «Издания органов научно-технической информации» — 57942

Read more

Summary

МАТЕРИАЛЫ И МЕТОДЫ

I. Идентификация риска — определение возможных опасных событий или потенциальных несоответствий. Анализ и оценка риска — определение уровня риска, вероятности его возникновения, масштаба воздействия, причин и последствий, приемлемости или недопустимости. Выбор метода анализа и оценки риска зависит от конкретного изучаемого процесса и ресурсов организации [1]. Принятие решения по риску — принятие решения по снижению риска, его устранению или принятию, выбор корректирующих и предупреждающих мероприятий. Анализ рисков проводили по методу «Анализ видов и последствий потенциальных несоответствий» (Failure Mode Effect Analysis, FMEA). По каждому риску по балльной системе оценивали тяжесть вреда последствий (S), вероятность возникновения опасности (О), вероятность выявления опасности (D) Определяющую характер предупреждающих мероприятий и срочность их проведения, характеризует приоритетное число риска (ПЧР), рассчитывающееся как произведение значений трех составляющих риска (S × O × D) Определяющую характер предупреждающих мероприятий и срочность их проведения, характеризует приоритетное число риска (ПЧР), рассчитывающееся как произведение значений трех составляющих риска (S × O × D) (табл. 2)

РЕЗУЛЬТАТЫ И ОБСУЖДЕНИЕ
Значительный риск Significant risk
Helicobacter pylori
Hemophilus parasuis
Сумма Total
Подписку на журнал можно оформить
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call